The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 941-948

  Feng, Yun ^a   Wan, Huanying ^a   Liu, Jialin ^a   Zhang, Ruifeng ^a   Ma, Q ^b   Han, Bing ^b   Xiang, Yi ^a   Che, Jiaming ^a   Cao, Huangming ^b   Fei, Xiaochun ^a   Qiu, Weicheng ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin II; Angiotensin converting enzyme 2; Non small cell lung cancer; Proliferation; Vascular endothelial growth factor a

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CELL CYCLE; CELL GROWTH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; TUMOR GROWTH; WESTERN BLOTTING;

ANGIOTENSIN II; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949442547     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000718     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 56: 106-130, 2006.
2. Brunner HR, Laragh JH, Baer L, et al: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441-449, 1972.
3. Fleming I, Kohlstedt K and Busse R: The tissue renin-angiotensin system and intracellular signaling. Curr Opin Nephrol Hypertens 15: 8-13, 2006.
4. Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S and Kikkawa F: Manipulating the angiotensin system - new approaches to the treatment of solid tumours. Expert Opin Biol Ther 6: 243-255, 2006.
5. Vinson GP, Ho MM and Puddefoot JR: The distribution of angiotensin II type 1 receptors, and the tissue reninangiotensin systems. Mol Med Today 1: 35-39, 1995.
6. Taylor GM, Cook HT, Sheffield EA, Hanson C and Peart WS: Renin in blood vessels in human pulmonary tumors. An immunohistochemical and biochemical study. Am J Pathol 130: 543-551, 1988.
7. Lever AF, Hole DJ, Gillis CR, et al: Do inhibitors of angiotensin-I converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998.
8. Ramos-Nino ME, Maclean CD and Littenberg B: Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont Diabetes Information System. BMC Endocrine Disorders 8: 17, 2008.
9. Prontera C, Mariani B, Rossi C, Poggi A and Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 31: 761-766, 1999.
10. Attoub S, Gaben AM, Salam SA, et al: Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann NY Acad Sci 1138: 65-72, 2008.
11. Harmer D, Gilbert M, Borman R and Clark KL: Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett 352: 107-110, 2002.
12. Gembardt F, Sterner-Kock A, Imboden H, et al: Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26: 1270-1277, 2005.
13. Donoghue M, Hsieh F, Baronas E, et al: A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E19, 2002.
14. Tipnis SR, Hooper NM, Hyde R, et al: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
15. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ and van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203: 631-637, 2004.
16. Ren X, Glende J, Al-Falah M, et al: Analysis of ACE2 in polarized epithelial cell: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 87: 1691-1695, 2006.
17. Turner AJ, Tipnis SR, Guy JL, Rice GI and Hooper NM: ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80: 346-353, 2001.
18. Vickers C, Hales P, Kaushik V, et al: Hydrolysis of biological peptides by human angiotensin converting enzyme-related carboxypeptidase. J Biol Chem 227: 14838-14843, 2002.
19. Santos RA, Campagnole-Santos MJ and Andrade SP: Angiotensin-(1-7): an update. Regul Pept 91: 45-62, 2000.
20. Zisman LS, Keller RS, Weaver B, et al: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108: 1707-1712, 2003.
21. Li N, Zimpelmann J, Cheng K, Wilkins JA and Burns KD: The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 288: F353-F362, 2005.
22. Campbell DJ, Zeitz CJ, Esler MD and Horowitz JD: Evidence against a major role for angiotensin converting enzymerelated carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 22: 1971-1976, 2004.
23. Gallagher PE and Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052, 2004.
24. Menon J, Soto-Pantoja DR, Callahan MF, et al: Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 67: 2809-2815, 2007.
25. Deshayes F and Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-299, 2005.
26. Egami K, Murohara T, Shimada T, et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003.
27. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M and Majima M: Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271-279, 2005.
28. Imai N, Hashimoto T, Kihara M, et al: Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 87: 189-198, 2007.
29. Raizada MK and Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50: 112-119, 2007.
30. Mizuiri S, Hemmi H, Arita M, et al: Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 51: 613-623, 2003.
31. Wang G, Lai FM, Lai KB, et al: Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 51: 1062-1067, 2008.
32. Koka V, Huang XR, Chung AC, Wang W, Truong LD and Lan HY: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/ p38 MAP kinase pathway. Am J Pathol 172: 1174-1183, 2008.
33. Gallagher PE, Chappell MC, Ferrario CM and Tallant EA: Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 290: c420-c426, 2006.
34. Itoh H, Mukoyama M, Pratt RE, Gibbons GH and Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993.
35. Cheng EY, Grammatopoulos T, Lee C, Sensibar J, Decker R and Kaplan WE: Angiotensin II and basic fibroblast growth factor induce neonatal bladder stromal cell mitogenesis. J Urol 156: 593-597, 1996.
36. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT and Yeo CJ: Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996-1005, 2007.
37. Zhou L, Zhang R, Yao W, Wang J, Qian A and Qiao M: Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med 217: 123-131, 2009.
38. Kim KJ, Li B, Winer J, Armanini M, Gillett N and Phillips HS: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 29: 841-844, 1993.
39. Kang YS, Park YG, Kim BK, et al: Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 36: 377-388, 2006.